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ABSTRACT: Antisense oligonucleotides (ASOs) have the poten-
tial to revolutionize medicine due to their ability to manipulate gene
function for therapeutic purposes. ASOs are chemically modiﬁed
and/or incorporated within nanoparticles to enhance their stability
and cellular uptake, however, a major challenge is the poor
understanding of their uptake mechanisms, which would facilitate
improved ASO designs with enhanced activity and reduced toxicity.
Here, we study the uptake mechanism of three therapeutically
relevant ASOs (peptide-conjugated phosphorodiamidate morpholi-
no (PPMO), 2′Omethyl phosphorothioate (2′OMe), and phos-
phorothioated tricyclo DNA (tcDNA) that have been optimized to
induce exon skipping in models of Duchenne muscular dystrophy
(DMD). We show that PPMO and tcDNA have high propensity to
spontaneously self-assemble into nanoparticles. PPMO forms micelles of deﬁned size and their net charge (zeta potential) is
dependent on the medium and concentration. In biomimetic conditions and at low concentrations, PPMO obtains net negative
charge and its uptake is mediated by class A scavenger receptor subtypes (SCARAs) as shown by competitive inhibition and
RNAi silencing experiments in vitro. In vivo, the activity of PPMO was signiﬁcantly decreased in SCARA1 knockout mice
compared to wild-type animals. Additionally, we show that SCARA1 is involved in the uptake of tcDNA and 2′OMe as shown by
competitive inhibition and colocalization experiments. Surface plasmon resonance binding analysis to SCARA1 demonstrated
that PPMO and tcDNA have higher binding proﬁles to the receptor compared to 2′OMe. These results demonstrate receptor-
mediated uptake for a range of therapeutic ASO chemistries, a mechanism that is dependent on their self-assembly into
nanoparticles.
KEYWORDS: Antisense oligonucleotides, self-assembly, nanoparticles, scavenger receptors, uptake mechanism, delivery
Antisense oligonucleotides (ASOs) can be designed totarget DNA and RNA in a sequence-speciﬁc manner to
stop, alter, or induce particular gene functions. Thus, they have
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emerged as a very promising new class of therapeutics that can
target disease pathophysiology at the molecular genetic level
with high speciﬁcity. One of the most advanced applications of
ASOs is their use for manipulation of gene function through
splice switching. ASOs can switch splicing patterns through
sequence-speciﬁc targeting of pre-mRNA elements involved in
exon recognition and/or consensus splice sites in a sequence-
speciﬁc manner.1 This approach has been investigated as
potential treatments for diﬀerent types of muscular dystrophies,
especially Duchenne muscular dystrophy (DMD), where ASOs
have been extensively tested in disease models and are currently
being evaluated in several clinical trials.2,3 DMD is caused by
loss of function of the DMD gene due to deletions and/or
mutations that cause the generation of premature termination
codons and/or out-of-frame transcripts.4 Targeting of splice
sites or putative exon splicing enhancers with ASOs can induce
the removal of exons from the mature DMD transcript such
that a nonsense mutation is bypassed, or alternately removal of
exons around a genomic deletion can restore the mRNA
reading frame.
Chemical modiﬁcations are introduced into ASOs to
enhance their stability against nucleases and to prevent immune
stimulation.5 Despite the promising results of the ongoing trials
using ASOs, major scientiﬁc challenges remain. The principle
limitation of ASOs is their poor cellular uptake due to their
large molecular weight and mostly highly charged nature.
Paradoxically, in practice ASO uptake is dramatically enhanced
when they are incorporated with nanoparticles that are even
larger in size and much richer in charge. Most transfection
reagents and ASO delivery systems rely on complexation or
loading ASOs into nanoparticulate vectors.6 Moreover, under
certain conditions, naked ASOs of diﬀerent chemistries are
taken up by cells without the need for transfection reagents in a
process termed “gymnosis” via an unknown mechanism.7 Thus,
understanding the uptake mechanism and resolving these
seemingly paradoxical observations is very important for the
clinical development of ASOs. Here we study the uptake
mechanism of three ASO compounds of diﬀerent chemistries
that have been optimized for skipping of exon 23 in preclinical
or clinical studies of DMD.
The ﬁrst compound is from the peptide-morpholino family
(PPMOs), which comprises a cell-penetrating peptide (CPP)
attached to phosphorodiamidate morpholino oligomer, PMO.8
PMOs possess a morpholino moiety instead of the ribose
moiety and the backbone phosphodiester linkages are replaced
with uncharged phosphorodiamidate linkages. CPPs are short
cationic peptides that enhance the uptake of the PMO into
cells.8 Here, we mainly use the B-peptide conjugated PMO (B-
PMO), a classical PPMO example, as our model.9 The second
ASO is from the second generation of chemically modiﬁed
RNAs; phosphorothioate 2′OMe. The 2′OH is replaced by a
2′OMe group and the phosphodiester linkages in the backbone
are replaced by the more stable phosphorothioate linkages.5
The third ASO is from the recently developed family of tricyclo
Figure 1. Characterization self-assembling nanoparticles. (A) DLS analysis of tcDNA, 2′OMe, and PPMO. Each was measured three times (diﬀerent
colors) at 1 mM concentration in PBS showing the proﬁle of the diﬀerent populations present. (B) Negatively stained TEM pictures of nanoparticles
formed by PPMO; bar = 100 nm. (C) CMC determination of PPMO using the dye micellization method (absorbance at 542 nm). Eosin Y
concentration: 0.019 mM. The X-axis represents log the concentration in nM. CMC is the inverse log of the point at the intersection between the
linear portion of the curve near the inﬂection point (R2 = 0.924) and the absorbance of the dye in the absence of any surfactant represented by the
horizontal line. CMC = 1380.38 nM. (D) PPMO at diﬀerent concentrations was loaded on a 1.25% agarose gel using TAE as running buﬀer.
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DNA (tcDNA). TcDNA has three additional C atoms between
C5′ and C3′ that increase both the aﬃnity and hydrophobicity
of the molecule together with a phosphorothioate backbone.10
Both 2′OMe and tcDNA chemistries have been shown to be
taken up by cells via gymnosis.7,11 All three molecules have
been extensively tested in the well-established mdx mouse
model for DMD, which carries a nonsense mutation in exon 23
of the DMD gene. Of the three ASO classes, PPMOs are the
most potent, achieving high levels of exon skipping in diﬀerent
skeletal muscles at doses as low as 6 mg/kg.9,12 TcDNA is the
second most potent chemistry tested here with a superior
activity over 2′OMe when administered at a dose of 200 mg/kg
demonstrating eﬀective exon skipping even in the brain.13
Recently, we have demonstrated that a class of pattern
recognition receptors (PRRs), namely scavenger receptors
(SRs), is involved in the uptake of certain CPPs when
complexed with ASOs.14 SRs are a large family of PRRs that are
involved in the uptake of pathogen associated molecular
patterns (PAMPs) and damage associated molecular patterns
(DAMPs) and play important functions in innate immunity and
homeostasis.15 They are subdivided into several classes, from A
to I, that are structurally diverse but functionally similar in their
ability to bind polyanionic (negatively charged) particulate
substrates.15,16 The vast array of their ligands include oxidized
low density lipoprotein (oxLDL), acetylated LDL (acLDL),
apoptotic cells, Staphylococcus aureus bacteria, HCV virus,
lipopolysaccharide (LPS), PrP prion protein, viral RNA, and
diﬀerent types of synthetic nanoparticles.15,17,18 Little is known
about the structural features that are responsible for the
promiscuous binding of SRs to negatively charged ligands;
however, it is hypothesized that the surfaces that are engaged in
ligand binding are similar in terms of shape and charge
distribution, displaying clusters of cationic residues (cationic
patches).15 Additionally, due to their observed low speciﬁcity
and functional overlap, they are thought to function in the form
of heteromultimeric receptor complexes (signalosomes) that
comprise SRs and other coreceptors.15 SRs are highly expressed
in professional immune cells such as macrophages but have also
been shown to be expressed other cell types including smooth
muscle cells, endothelial cells, ﬁbroblasts, splenic dendritic cells,
and epithelial cells.19 Class A SRs (SCARAs) are among the
most extensively studied SRs and are characterized structurally
by their collagenous domains.20 SCARAs have diﬀerent
subtypes, including SCARA1 (SR-AI), SCARA2 (MARCO),
SCARA3, SCARA4 (Colec12), and SCARA5, among which
SCARA3 and SCARA5 have been shown earlier to be involved
in uptake of CPP-ASO nanocomplexes.14
Here we study the eﬀects of the physicochemical properties
of the three diﬀerent ASO compounds (PPMO, phosphor-
othioate 2′OMe, phosphorothioate tcDNA) used for the
treatment of DMD and the role of SRs in their uptake,
especially in muscle cells. We hypothesize that variation in ASO
activity is due to their physicochemical properties modulated by
their ability to self-assemble and to bind to SRs.
Results and Discussion. PPMO and tcDNA with High
Propensity To Spontaneously Self-Assemble into Nano-
particles. Physicochemical properties including particle size
and charge are important determinants for uptake of drug
delivery systems. Recently, using transmission electron
microscopy (TEM) and nanoparticle tracking analysis, we
found that tcDNA has a higher propensity to self-assemble into
nanoparticles compared to 2′OMe.13 To investigate this further
in comparison to the PPMO chemistry we used dynamic light
scattering (DLS). In accordance with our previous observa-
tions, the predominant peak in the tcDNA sample was a broad
particulate peak (Figure 1A). For PPMO, there were two peaks,
one for singular molecules and one representing a particulate
population. However, for 2′OMe, the predominant peak was of
singular molecules at around 2 nm together with another
particulate peak of much less intensity (Figure 1A).
Comparatively, these results show that both tcDNA and
PPMO have a higher propensity to form nanoparticles than
2′OMe. In order to make sure that this property of self-
assembly is retained in physiological conditions, we repeated
the DLS measurements after incubation with physiological
concentrations of albumin solution in PBS for 1 h at 37 °C.
Albumin is the most abundant serum protein representing up
to 50% of total serum protein.21 While it is diﬃcult to run DLS
in the presence of full serum due to high background from
diverse proteins, a simpliﬁed albumin-based model generates
one distinct peak of albumin around 4 nm, which also acts as an
internal standard. Importantly, in this model, only tcDNA and
PPMO were able to display high intensity particulate peaks,
while 2′OMe failed to do so (Supporting Information Figure
S1A). To test full serum conditions on these ASOs,
ﬂuorescently labeled tcDNA and PPMO were incubated with
full serum for 1 h at 37 °C and subsequently fractionated using
a continuous sucrose gradient. The fraction with the highest
ﬂuorescence signal was visualized via ﬂuorescence microcopy.
Densely bright particulate structures were observed for tcDNA
and PPMO under these conditions, showing that the process of
self-assembly into nanoparticles is maintained in physiological
conditions and in the presence of serum proteins (Supporting
Information Figure S1B).
Amphipathic PPMO Forms Micelles. To further investigate
the nanoparticles formed by the PPMO, we used TEM
visualization, as used previously for tcDNA and 2′OMe.
PPMOs formed well-deﬁned nanoparticles with a diameter
ranging between 30 and 90 nm (Figure 1B). We speculated that
this spontaneous nanoparticle formation is due to the
amphipathicitiy of the PPMO structure that leads to self-
assembly into micelles. The PPMO molecule is composed of a
relatively hydrophobic PMO portion and a very hydrophilic
CPP that harbors multiple positive charges, a structure
susceptible to micelle formation. In fact, PMOs are among
the most hydrophobic ASO chemistries available. A PMO
adenosine monomer has an octanol−water partition coeﬃcient
(log P) of −2.72, while the log P for an adenosine nucleotide of
the 2′OMe chemistry is −4.15, −4.39 for locked nucleic acid
(LNA), and −3.43 for peptide nucleic acid (PNA).22 To
conﬁrm the micellization of PPMO, we utilized the dye
micellization method,23 which is a classical method used to
determine the critical micelle concentration (CMC). CMC is
the concentration at which an amphipathic surface active
molecule (surfactant) starts to self-assemble into micelles in the
bulk of the dispersion medium.23 Dyes such as eosin,
rhodamine and Sudan red are known to show a shift in the
wavelength maximum (λ max) due to the presence of
micelles.23 Here, we used eosin Y which has wavelength
maximum at 518 nm in water; however, the presence of
micelles increases its absorbance at 542 nm. CMC can be
determined by plotting the change in absorbance of the
micellized dye at a ﬁxed wavelength (542 nm) against
surfactant concentration. The linear portion near the inﬂection
point is extrapolated to intersect with the absorbance of the dye
in the absence of any surfactant (represented by the horizontal
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line in Figure 1C), and this concentration is the CMC.23
PPMO behavior was typical surfactant behavior with a CMC of
about 1.4 μM. The PPMO probably behaves similarly to
multihead-group surfactants; however, the complexity of the
structure due to the presence of an atypical hydrophobic tail
(the PMO in this case) and up to 10 charges might require the
development of speciﬁc models to understand this process.
PPMO Charge Reversal in Biomimetic Conditions. The net
charge of a nanoparticle is a function of pH and the
concentration of counterions in the medium. Thus, it is
important to study the properties of therapeutic compounds in
biomimetic conditions in terms of pH or isotonicity where their
properties at these conditions are more relevant to their
biological activity. We have previously demonstrated that
certain CPPs, such as PF14, which is used for ASO delivery
via noncovalent complexation, change their zeta potential
according to the dispersion medium.14 To determine if the
same is true for the self-assembled nanoparticles of PPMO, we
measured the zeta potential in diﬀerent conditions. Interest-
ingly, PPMOs displayed the same pattern, having a positive zeta
potential (10 ± 2.70) in water while changing into negative
values in PBS (−1.21 ± 0.63) and serum-free medium (−3.48
± 2.31) due to the change in pH and high salt concentration.
Surprisingly, this charge reversal was also concentration
dependent as demonstrated by gel mobility shift assay (Figure
1D). At high concentrations (50 μM), PPMO migrates toward
the cathode, indicating a net positive charge, but as the
concentration gets lower, the migration pattern shifts toward
the anode indicating a net negative charge in a clear
visualization of the charge reversal phenomenon. These
observations highlight the importance of the presence and
concentration of counterions in the solution. An important
parameter to consider here is ξ, which is the molar
concentration ratio of counterions to surfactant.24 When ξ
increases, more counterions bind to the micellar surface
changing its net charge and this explains the concentration
dependent charge reversal. At higher PPMO concentrations ξ is
low; hence, there are not enough counterions in the running
buﬀer to shield and reverse the exposed cationic groups on the
micellar surface; and thus, migration occurs toward the cathode.
As the PPMO concentration is decreased, the ξ ratio changed
in favor of the concentration of counterions in the running
buﬀer enabling shielding and reversal of the net surface charge
and migration to the opposite pole. The same eﬀect can be
replicated by keeping the PPMO concentration constant while
changing the concentration of the counterions. When using
TBE as a running buﬀer with equimolar concentrations of the
cationic basic species (Tris base) and the anionic acidic species
(boric acid), PPMO migration pattern can be seen to be
divided between both the anode and the cathode (Supporting
Information Figure S1C). Interestingly, when using unbalanced
TBE with excess basic species, the migration pattern shifts
toward the cathode indicating net positive charge, and the
opposite takes place upon using TBE with excess boric acid.
This further supports our hypothesis that the net charge of the
PPMO depends on the delicate balance between the
concentration of the PPMO and the concentration of the
counterions available in the medium.
Class A Scavenger Receptors Involved in PPMO Uptake. As
aforementioned, we have shown previously that the uptake of
certain CPP complexes with ASOs is mediated by class A
scavenger receptor subtypes (SCARAs).14 To determine
Figure 2. Involvement of SCARA in PPMO uptake. (A) Diﬀerentiated C2C12 cells (1 × 105) were pretreated SR ligands and control (fucoidin
sulfate, dextran sulfate, and chondroitin sulfate) at 50 μg/mL for 1 h then treated with PPMO (500 nM) for 4 h in Opti-MEM before changing the
medium to diﬀerentiation medium and incubation for 20 h. The products of nested reverse transcription-PCR (RT-PCR) were examined by
electrophoresis on a 2% agarose gel. The top band indicates full-length transcript and the bottom band represents exon-skipped transcript (B)
C2C12 myoblasts diﬀerentiated for 1 d, then treated with either siRNA cocktail targeting SACRA1,2,4 and 5 (25 nM each) using Lipofectamine
RNAiMax or scrambled control siRNA (Cntrl. siRNA, 100 nM). After 24 h, medium was changed and cells treated with PPMO (500 nm) as stated
above. The products of nested RT-PCR were examined by gel electrophoresis and the percent of exon skipping was calculated using densitometry.
(C) Quantitative PCR (qPCR) analysis of dystrophin exon 23-skipping in tibialis anterior muscle (TA), diaphragm and heart 1 week following
intravenous injection of 10 mg/kg PPMO (Pi6a-PMO) in adult SCARA1−/− and wild-type (WT) C57 BL/6 mice (n = 4). The percentage of exon
23-skipping of the DMD transcripts was determined by normalizing exon 23−24 ampliﬁcation levels to exon 20−21 levels. *P < 0.05; Student’s t-
test; error bars represent mean ± SEM.
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whether the change in charge of the PPMO also mediates
uptake through SCARAs, we tested the eﬀects of SCARA
ligands on the PPMO splice-switching activity in the C2C12
muscle cell line. Fucoidin sulfate and dextran sulfate are well-
known SCARA ligands, and chondroitin sulfate is a chemically
related molecule but not a speciﬁc ligand and thus serves as a
negative control. Cells were treated with the ligands or the
control for 1 h before treatment with the PPMO for 4 h, after
which the medium was changed and cells were incubated for 20
h. Both fucoidin sulfate and dextran sulfate completely inhibited
the splice-switching activity of the PPMO while chondroitin
sulfate had no eﬀect (Figure 2A). This competitive inhibition
demonstrates the involvement of SCARAs in the uptake and
activity of PPMO.
Moreover, several SCARA subtypes were expressed in the
C2C12 murine myoblast cell line, including SCARA1, 3, 4
(COLEC12), and 5 (Supporting Information Figure S2A). We
next tested the eﬀect of silencing the expressed SCARA
subtypes on PPMO activity. Upon using an siRNA cocktail
against all the expressed SCARA subtypes (1, 3, 4, and 5), the
splice-switching activity of PPMO was signiﬁcantly reduced
(Figure 2B). We have recently demonstrated that the uptake
and activity of PPMOs was higher in diﬀerentiated myotubes
compared to undiﬀerentiated myoblasts both in C2C1225 and
H2k mdx cell-lines,26 both of which represent common models
to study muscle diﬀerentiation. Interestingly, the expression of
SCARA subtypes increases signiﬁcantly throughout the course
of diﬀerentiation of both cell lines, which correlates closely with
the observed diﬀerence in PPMO uptake and activity
(Supporting Information Figure S2). Additionally, we per-
formed TEM and SCARA inhibition analysis to ensure that this
PPMO (Pip6a-PMO) behaves similarly to the model PPMO
we are testing here (B-PMO). Pip6a peptide design is broadly
similar to the B-peptide but with the inclusion of a YQFLI core
motif within the arginine rich sequence.27 This change
enhanced its splice-switching activity in vivo especially in the
heart; however, the cause of this enhanced activity was not
known. Here we show that Pip6a-PMO, similar to the B-PMO,
spontaneously forms nanoparticles that can be visualized via
TEM and that its uptake is signiﬁcantly inhibited in the
presence of SR ligands (Supporting Information Figure S3).
Interestingly, Pip6a-PMO nanoparticles are smaller than B-
PMO nanoparticles, a property that may contribute to its
enhanced biodistribution proﬁle. Importantly, when injected in
vivo in SCARA1 knockout mice,28 the activity of Pip6a-PMO
was signiﬁcantly reduced in the diaphragm and heart compared
to wild-type (WT) mice (Figure 2C). This demonstrates that
the SR-dependent interactions observed in vitro also contribute
to the biological activity of PPMOs in vivo. This does not
exclude however the involvement of other receptor subtypes
(SCARA3, 4, and 5) and other SR classes in this process. The
residual activity in the diaphragm and nonsigniﬁcant diﬀerences
in tibialis anterior (TA) might very likely be due to
compensation and diﬀerential expression of other SRs that
are not altered in their expression in this model.
It is important to note that these observations for PPMOs
could have more general implications on understanding the
mechanism of action of both CPPs and antimicrobial peptides
(AMPs). Several secondary amphipathic CPPs are known to
self-assemble into nanoparticles.29 Furthermore, Kohno et al.30
Figure 3. Role of SRs in the uptake of tcDNA and 2′OMe. (A) Diﬀerentiated C2C12 cells (2.5 × 104/cm2) were pretreated with SR ligands
including fucoidin sulfate or polyinosinic acid (poly I), and controls including chondroitin sulfate or polycytidylic acid (poly C), at 100 μg/mL for 1
h. Then cells were incubated with FITC-2′OMePS (200 nM) or FITC-tcDNA (200 nM) for 4 h and visualized by ﬂorescence microscopy. Scale bar,
20 μm. (B) Quantitative ﬂuorescence image analysis, mean ﬂuorescence intensity was quantiﬁed using ImageJ software. *P < 0.05, **P < 0.01, ***P
< 0.001; one-way ANOVA, error bars represent mean ± SEM.
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have recently shown that the uptake of an antimicrobial peptide
(K8L9) at subcytotoxic concentrations is mediated by neuro-
pilin-1 and low-density lipoprotein-related protein receptor 1
(LRP1), a receptor with scavenger like properties. Moreover,
using siRNA screens, Kondo et al.31 demonstrated the
involvement of M160 (CD163L1; scavenger receptor cys-
teine-rich type I) in the uptake of a tumor homing CPP
(CPP44). This shows that the phenomena of self-assembly and
SR interaction are more general and that several SR receptor
classes might be involved in the CPP/AMP mechanism of
action; however, the details of their complementary, synergistic,
or compensatory mechanisms require further studies. Addi-
tionally, the observation that net charge is dependent on
concentration might explain diﬀerent mechanisms of activity for
CPPs and/or AMPs. At low concentrations, when there are
suﬃcient counterions to shield and reverse the positive charge,
receptor-mediated uptake might be the predominant mecha-
nism of action. However, at high concentrations, when the net
charge is positive, direct membrane interactions might
predominate, which could explain lytic and toxic eﬀects at
such concentrations.
Varied Involvement of SRs in the Uptake of PPMO, tcDNA
and 2′OMe Chemistries. To determine the involvement of SRs
in the gymnotic uptake of the other ASO chemistries we tested
the eﬀect of several SR ligands on the uptake of naked tcDNA
and 2′OMe. The uptake of FITC-tcDNA and FITC-2′OMe
was monitored in the presence of polyinosinic acid (poly I),
polycytidylic acid (poly C), fucoidin sulfate, dextran sulfate, and
chondroitin sulfate. While fucoidin and dextran sulfates are
more speciﬁc for SCARAs, poly I is more general as it also
targets class C (SR-CI), class E (ORL-1/Lox-1), and class F
(SREC) SRs32 in addition to other receptors with scavenger
properties such as Mac133 and nucleolin which binds
quadruplex DNA structures.34,35 Poly C serves as the control
for poly I. The uptake of tcDNA and 2′OMe was only partially
inhibited in the presence of fucoidin and dextran sulfates but
almost completely inhibited in the presence of poly I (93.6 and
89.0% respectively) (Figure 3) demonstrating the involvement
of SCARAs together with other poly I sensitive SRs in the
uptake, probably in heteromultimeric signalosome complexes.
SRs have been previously suggested to be involved in the
uptake of negatively charged ASOs,36−39 and it has been shown
that the formation of multimers or the capacity to form G-
quadruplexes enhance the uptake and activity of naked
ASOs.40−42 This aggregation was also shown to enhance
binding to SRs.43,44 Thus, it is feasible to speculate that the
superior activity of tcDNA is related to its propensity to self-
assemble into nanoparticles mediating better SR interaction
and subsequent gymnotic uptake. Indeed, we observed that the
extent of uptake of ﬂuorescently labeled tcDNA is signiﬁcantly
higher than that of 2′OMe despite having similar biological
activity upon lipofection (Supporting Information Figure S4).
Equivalent biological activity using lipofection was also
demonstrated using sequences targeting exon 51 (Supporting
Information Figure S4D). This shows that despite other factors
that might contribute to the superior activity of tcDNA (mRNA
binding for example) a higher uptake proﬁle due to higher
propensity to form nanoparticles signiﬁcantly contributes to
this increased activity. This is more evident in the case of
PPMO, which displays several folds higher uptake than the
Figure 4. Interaction with SCARA1. (A) Representative images of the cellular colocalization of Cy5-PPMO or FITC-2′OMePS and FITC-tcDNA
with rat antimouse SCARA1 antibody in diﬀerentiated C2C12 myotubes at 4 h as measured by ﬂuorescence microscopy (Cy5- PPMO, FITC-
tcDNA and FITC- 2′OMePS were used at 200, 500, and 500 nM, respectively). Scale bar, 20 μm. (B) Binding experiments were performed using a
Biacore 3000 system. His-tagged SCARA1 receptor was immobilized on the chip using an antihis-tag antibody to give <420 RU. Diﬀerent ASOs in
PBS were injected at 10 μL/min at 25 °C. Data traces were zeroed in the x- and y-axis after subtraction of nonspeciﬁc binding.
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other two chemistries (Supporting Information Figure S4).
Furthermore, we studied the eﬀect of other factors on the
uptake of the ASOs. Incubation at 4 °C signiﬁcantly reduced
the uptake of all the chemistries indicating the involvement of
an active, energy-dependent mechanism of uptake (Supporting
Information Figure S4). Incubation in the presence of serum on
the other hand had only a small negative eﬀect on uptake
(Supporting Information Figure S4), which might be due to the
high stability of these heavily chemically modiﬁed ASOs.
The mechanism of spontaneous tcDNA self-assembly is not
well understood. While tcDNA lacks the dichotomy of
structure of the PPMO, the three additional C atoms increase
the hydrophobicity of the molecule. We speculate that this
increased hydrophobicity might impart secondary amphipathic
properties on the structure enabling self-assembly via
mechanisms resembling the self-assembly of secondary
amphipathic peptides.29 Alternatively, the extra rings in the
tcDNA might facilitate stacking and generation of structures
resembling poly-G aggregates that were seen to enhance the
uptake of ASOs and binding to SRs.41−44 Structural and
molecular modeling studies are underway to unravel the
mechanism of tcDNA self-assembly.
Co-localization and SCARA1 Binding. To demonstrate
direct association between ASOs and receptor we performed
colocalization experiments and surface plasmon resonance
(SPR) binding analysis. Immunocytochemical analysis using an
anti-SCARA1 antibody showed colocalization of all three ASO
compounds with the receptor (Figure 4A). Furthermore, SPR
was used to comparatively study the relative binding of the
diﬀerent chemistries to SCARA1. His-tagged SCARA-1
receptors were immobilized on the chip using an anti-His-tag
antibody. Response units were calculated for speciﬁc binding
after subtraction of nonspeciﬁc binding to the chip or the
antibody. PPMO demonstrated the highest binding followed by
tcDNA, while 2′OMe displayed minimal binding (Figure 4B).
It was evident that the chemistries that are able to form
nanoparticles demonstrated more eﬃcient binding to the
receptor, which is in accordance with the mode of action of
SRs.
Conclusions. Our data shows that two potent ASOs,
PPMO and tcDNA, have a higher propensity to self-assemble
into nanoparticles and better binding to SCARA1 compared to
the less potent 2′OMe. We hypothesize that nanoparticle
assembly enhances ASO uptake based on the particle-wrapping
model for receptor-mediated uptake of nanoparticles.45,46 In
this model, optimal uptake requires a certain threshold of
particle size. Below this threshold, uptake will be impeded by
the high energy cost required for a high curvature of the
membrane to wrap the particle, and above it the uptake will be
limited by the number of the receptors available for eﬃcient
particle wrapping.47 An optimal radius for uptake has been
predicted theoretically to be around 25−30 nm and has also
been validated experimentally.48 Interestingly, TEM pictures
show that both PPMO and tcDNA13 nanoparticles are within
this size range. Thus, the self-assembly process is important for
mediating this type of interaction through SRs. The importance
of the self-assembly process for uptake can be depicted in a
model where single ASO molecules fail the criteria required for
passive uptake into cells due to charge and size restrictions
(Lipinski rule of 549); however, they can gain access via
receptor-mediated endocytosis only if they reach a certain size
threshold (particle-wrapping model) (Figure 5).
Unlike preformed synthetic nanoparticles, this process is
spontaneous and dynamic, which means that the particles form
and deform under diﬀerent conditions. However, the apparent
high propensity to self-assemble increases the probability of
PPMO and tcDNA to form nanoparticles in proximity to the
cell surface compared to other chemistries. In this regard,
PPMOs and tcDNA resemble in vivo nanoparticle-based
delivery systems and in vitro transfection reagents without
the need for exogenous delivery or complexing agents.
Furthermore, the spontaneous and reversible nature of the
self-assembly process can explain the enhanced biodistribution
of PPMOs and tcDNAs to tissues that are inaccessible to
Figure 5. An illustration describing the relation between two diﬀerent models of cellular uptake. Singular molecules follow the Lipinski rule of 549
(molecular weight is less than 500 Da, lipophilicity-expressed as is less than 5, the number of hydrogen bond donators is less than 5, and the number
of hydrogen bond acceptors is less than 10). This leads to sharp decrease in uptake with increasing size and charge of a molecule. That is why
singular naked ASOs fail to cross cell-membranes. However, when they reach a certain size, either by self-assembly or incorporation into
nanoparticle-based delivery vectors, they lie within the scope of the receptor-mediated uptake process, especially through pattern recognition
receptors of the innate immune system such as scavenger receptors. For this process to take place, the nanoparticles have to possess a minimum
radius (rminimum, around 22 nm).
45 Beyond an upper limit (rmaximum, around 60 nm) uptake starts to drop once more. Below the minimum radius,
uptake is impeded by the high energy cost required for high curvature of the membrane for particle wrapping, and above the maximum radius uptake
will be limited by the number of the receptors available for eﬃcient particle interaction.47
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conventional nanoparticles, like skeletal muscle for example.
While preformed nanoparticles are unable to extravasate into
most tissues except liver and spleen due to the size restriction
of capillary fenestrations, we speculate that self-assembling
chemistries are able to extravasate through capillary fenestra-
tions as single molecules and reform nanoparticles upon
accumulation and reaching high local concentrations in situ.
However, more in vivo pharmacokinetic and biodistribution
studies are needed to elucidate these mechanisms in more
detail as a limitation of in vitro cell systems is that they
diﬀerentially express proteins on their surface when compared
to in vivo conditions.
We believe that such models are crucial for understanding
the pharmacokinetics and dynamics of current ASO ther-
apeutics for better design and development of new ASO
chemistries and delivery vehicles. On the basis of the ﬁndings
discussed above, novel drug delivery platforms can be designed
to enhance the propensity of self-assembly or to target
SCARAs. These ﬁndings also highlight the importance of
understanding the uptake mechanism for the clinical develop-
ment of ASOs and pave the way for successfully applying ASOs
to the treatment of genetic diseases.
Methods. Antisense Oligonucleotides (ASOs). All ASOs
target the donor splice site of exon 23 of the mouse dystrophin
pre-mRNA. The most eﬃcient sequence was chosen for all
chemistries from previously reported studies. TcDNA-PS (5′-
AACCTCGGCTTACCT-3′) was synthesized by SYNTHENA,
Bern. 2′OMePS (5′-GGCCAAACCUCGGCUUACCU-3′)
was synthesized by Integrated DNA Technologies (IDT,
U.S.A.) and PMO (5′-GGCCAAACCTCGGCTTACCT-
GAAAT-3′) was ordered from Gene Tools LLC. Conjugations
of peptide (B-peptide, RXRRBRRXRRBRXB; Pip6a,
RXRRBRRXR YQFLI RXRBRXRB, X, 6-aminohexanoic acid;
B, b-alanine) with PMO were synthesized through use of a
stable amide linker as described elsewhere.50
DLS, TEM, CMC, and Zeta Potential. DLS measurements
were performed on Viscotek 802 instrument (Malvern, U.S.A.)
using 30 μL of 1 mM ASO in PBS. DLS measurements in
simulated physiologic conditions were performed by mixing
equal volumes of the ASOs with ﬁltered albumin (BSA, Sigma-
Aldrich, Germany) solution in PBS (4.25 g/dL) at 37 °C for 1
h then measuring on the DLS machine after appropriate
dilution (10×). For TEM visualization, PPMO was mounted
on Formvar/carbon coated 200 mesh nickel grids (Agar
Scientiﬁc, U.K.), then negatively stained using an aqueous
solution of uranyl acetate and visualized using a JEOL 1010
transmission electron microscope (JEOL, Peabody, MA,
U.S.A.) at 50 000× magniﬁcation. For CMC measurements,
eosin Y at a ﬁnal concentration of 0.019 mM was mixed with
diﬀerent concentrations of PPMO (50, 25, 15, 12, 10, 9, 8, 7, 6,
5, 4, 3, 2, 1, 0.5, 0.25, 0.125 μM). UV absorption was measured
at 542 nm using Biotek Synergy HT spectrophotometer
(Biotek, U.S.A.). Zeta potential measurements were carried out
on a Zetasizer instrument (Malvern, U.S.A.). Charge reversal
gel experiments were run on 1.25% agarose gel with ethidium
bromide using diﬀerent buﬀers including TAE, TBE, TBE with
4× Tris, and TBE with 4× boric acid and visualized using UV.
For visualization nanoparticles in serum, FITC-labeled ASOs
were incubated in 100 μL of whole serum at a ﬁnal
concentration of 10 μM (fetal bovine serum, heat inactivated
(FBS)) for 1 h at 37 °C. After incubation, ASOs were layered
on top of a sucrose gradient. The gradient was composed of
seven 1.25 mL fractions of sucrose dissolved in PBS. The
concentrations of the fractions from the top to the bottom were
15%−45% in 5% increments. Once layered, the gradients’
interfaces were smoothened through diﬀusion by vertical
incubation at 4 °C overnight. The loaded gradients were
spun in an ultracentrifuge (Beckman Coulter OptimaLE 80 K)
using a swinging bucket rotor (Beckman Coulter, SW 41Ti) at
200 000× g for 4 h at 4 °C. The gradients were then retrieved
and 1 mL fractions from top to bottom were collected (10
fractions in total per ASO). One hundred microliters per
fraction were transferred to a clear bottom black plate and
screened for ﬂuorescence signal. The fractions with highest
signal were loaded on a sandwiched coverslip-slide (two spacers
made of double sided tape were used to ﬁx the coverslip on the
slide) treated with 50 μL of a 5 mg/mL BSA in PBS solution
for 10 min and subsequently imaged using an oil immersion
100× objective in a Nikon Eclipse TE2000-U equipped with a
Watec WAT-902H camera.
Cell Culture and PCR. Murine C2C12 cells were grown in
DMEM (Dulbecco’s Modiﬁed Eagle Medium), high glucose,
GlutaMAX media (Life Technologies, U.S.A.) with 10% fetal
bovine serum (FBS, Life Technologies) and 1% penicillin/
streptomycin (Life Technologies). Murine H2k mdx myoblasts
were cultured in gelatin (0.01%)-coated ﬂasks at 33 °C under
10% CO2 in Dulbecco’s modiﬁed Eagles medium (DMEM
PAA laboratories) supplemented with 20% heat-inactivated
fetal bovine serum (FBS Gold, PAA laboratories), 2% chicken
embryo extract (Seralab), 1% penicillin/streptomycin-neo-
mycin antibiotic mixture (Life Technologies), and 3 pg/mL
g-interferon (PeproTech). For diﬀerentiation, cells (1 × 105)
were seeded into wells of a 24-well plate and the medium was
changed after 24 h into diﬀerentiation medium consisting of
DMEM containing 2% horse serum (Life Technologies) and
diﬀerentiated for 3−4 days before experimentation. For PPMO
treatment, cells were treated with a concentration of 500 nM in
serum-free Opti-MEM medium for 4 h, the medium was then
changed for diﬀerentiation medium and incubation continued
for a further 20 h. For RT-PCR detection of exon skipping, cells
were lysed and RNA-harvested using RNeasy kit (Qiagen,
Germany) and quantiﬁed then used for nested PCR procedure.
Brieﬂy, RNA was ampliﬁed on two steps with gene-speciﬁc
primers (Ex 20−26, Fwd, CAG AAT TCT GCC AAT TGC
TGA G−; Rev, TTC TTC AGC TTG TGT CAT CC) using
Gene Amp PCR core kit (Life Technologies). Then cDNA was
further ampliﬁed using Amplitaq Gold polymerase (Life
Technologies, U.S.A.) with primers, Ex 20−26, Fwd, CCC
AGT CTA CCA CCC TAT CAG AGC; Rev, CCT GCC TTT
AAG GCT TCC TT). PCR products were examined by
electrophoresis on a 2% agarose gel. qPCR analysis was
performed on cDNA from C2C12 and H2k mdx cells using 25
ng cDNA template and ampliﬁed with Taqman Gene
Expression Master Mix (Applied Biosystems, Warrington,
U.K.) on a StepOne Plus Thermocycler (Applied Biosystems,
Warrington, U.K.). Taqman probes targeting SCARA1/3/4/5
(Life Technologies) were used and murine glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) probes were used as an
internal control for cDNA levels.
Scavenger Receptor (SR) Inhibition. Diﬀerentiated C2C12
or H2k mdx (1 × 105) were treated with SR ligands and
controls, that is, fucoidin sulfate, dextran sulfate, chondroitin
sulfate, polyinosinic acid, polycytidylic acid (Sigma-Aldrich,
Germany), for 1 h before adding the ASOs. Cells were then
treated with the ASOs and analyzed as stated above. For siRNA
treatment, C2C12 myoblasts diﬀerentiated for 24 h were
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treated with either a cocktail of siRNAs, SACRA1, 2, 4, and 5,
25 nM each (siGenome SMART pool, Dharmacon, U.S.A.), or
scrambled control siRNA (100 nM) using Lipofectamine
RNAiMax (Life Technologies) according to the manufacturer’s
protocol. After 24 h, the medium was changed and cells were
treated with PPMO as explained earlier.
Animal Experiments. Experiments were carried out in the
Biomedical Sciences Unit, University of Oxford according to
procedures authorized by the UK Home Oﬃce. SCARA1 −/−
and C57BL/6 mice (14 months old, n = 4) were used.
SCARA1−/− mice were generated by Professor Tatsuhiko
Kodama,28 and a colony has been maintained in our lab since
then. Pip6-PMO conjugates were prepared in 0.9% saline
solution at a ﬁnal dose of 10 mg/kg and administered via the
tail vein. One week later mice were sacriﬁced by CO2 inhalation
and tissues harvested and snap-frozen in cooled isopentane
before storage at −80 °C. Total RNA was extracted from
tissues using TRIzol reagent (Life Technologies) following
manufacturer’s instructions. For quantitative analysis of exon
skipping levels, 1 μg of RNA was reverse transcribed using the
high capacity cDNA RT Kit (Applied Biosystems, Warrington,
U.K.) according to manufacturer’s instructions. qPCR analysis
was performed using 25 ng cDNA template and ampliﬁed with
Taqman Gene Expression Master Mix (Applied Biosystems,
Warrington, U.K.) on a StepOne Plus Thermocycler (Applied
Biosystems, Warrington, U.K.). Levels of Dmd exon 23
skipping was determined by multiplex qPCR of FAM-labeled
primers spanning Exon 20−21 (Assay Mm.PT.47.9564450,
Integrated DNA Technologies, Leuven, Belgium) and HEX-
labeled primers spanning Exon 23−24 (Mm.PT.47.7668824,
Integrated DNA Technologies). The percentage of DMD
transcripts skipping exon 23 was determined by normalizing
DMD exon 23−24 ampliﬁcation levels to DMD exon 20−21
levels.
Fluorescence Microscopy and Spectrophotometry. For
immunoﬂuorescence, cells were treated with either Cy5
conjugated PPMO,51 or FITC conjugated 2′OMePS or
tcDNA oligonucleotides for 4 h then washed 3 times with
PBS plus (PBS containing Ca2+ and Mg2+) solution and ﬁxed
with methanol at −20 °C for 10 min. Cells were then washed
and stored in PBS at 4 °C for future immunoﬂuorescence. For
colocalization, cells were treated with 0.1% Triton-X100
(Sigma-Aldrich) in PBS for 10 min and washed three times
with PBS plus, then blocked with 1% bovine serum albumin
(BSA, Sigma-Aldrich) containing PBS for 1 h. Cells were then
incubated with rat antimouse SCARA1 (1:200 dilution, Bio-
Rad, Hercules, CA) then washed three times with PBS plus and
treated with 1:500 Alexa Fluor 488 goat antirat (Life
Technologies) for 1 h. DAPI (1:5000 dilution, Sigma-Aldrich)
staining was then completed for 2 min, after which cells were
washed and mounted with ﬂuorescent mounting medium
S3023 (Dako, Tokyo, Japan) onto glass slides. Visualization was
carried out on a Leica ﬂuorescent microscope with pictures
taken by Axiovision ﬂuorescent camera and Axiovision software
(Zeiss, Oberkochen, Germany). Spectrophotometric measure-
ments for the uptake of FITC-labeleld ASOs were performed in
tissue-culture coated black plates with clear optical bottom
(Corning, U.S.A.) using Victor3 spectrophotometer (Perki-
nElmer, U.S.A.) 24 h after ASO addition.
SPR. Binding experiments were performed with a Biacore
3000 system (GE Healthcare) using CM5 chip. Antihis-tag
antibody was immobilized using amine coupling. Subsequently,
His-tagged recombinant mouse SR-AI (SCARA1) (R&D
Systems, U.S.A.) receptor was immobilized on a CM5 chip to
give <420 RU. For the binding assay, ASOs in PBS were
injected at 10 μL/min at 25 °C. Data traces were zeroed in the
x- and y-axis after subtraction of nonspeciﬁc binding.
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